A daring treatment and a successful outcome: The need for targeted therapies for pediatric respiratory viruses

Pediatric Transplantation

Volumn 11, Issue 2, 2007, Pages 121-123

  DeLaMora, Patricia ^a   Moscona, Anne ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NUCLEOSIDE ANALOG; RIBAVIRIN; STEROID;

COMBINED IMMUNODEFICIENCY; EDITORIAL; GRAFT VERSUS HOST REACTION; HUMAN; PARAINFLUENZA VIRUS 3; PARAINFLUENZA VIRUS INFECTION; RESPIRATORY VIRUS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRAL RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

AEROSOLS; ANTIVIRAL AGENTS; CHILD; HUMANS; INFANT; PARAINFLUENZA VIRUS 3, HUMAN; RESPIROVIRUS INFECTIONS; RIBAVIRIN; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 33846606109     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2006.00654.x     Document Type: Editorial

References (18)

1. ALYMOVA IV, PORTNER A, TAKIMOTO T, BOYD KL, BABU YS, MCCULLERS JA. The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2005: 49: 398-405.
2. ELIZAGA J, OLAVARRIA E, APPERLEY J, GOLDMAN J, WARD K. Parainfluenza virus 3 infection after stem cell transplant: Relevance to outcome of rapid diagnosis and ribavirin treatment. Clin Infect Dis 2001: 32: 413-418.
3. GROOTHUIS J, SIMOES E, LEVIN M, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993: 329: 1524-1530.
4. HUBERMAN K, PELUSO R, MOSCONA A. The hemagglutinin-neuraminidase of human parainfluenza virus type 3: Role of the neuraminidase in the viral life cycle. Virology 1995: 214: 294-300.
5. LAWRENCE MC, BORG NA, STRELTSOV VA, et al. Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III. J Mol Biol 2004: 335: 1343-1357.
6. LOUGHLIN GM, MOSCONA A. The cell biology of acute childhood respiratory disease: Therapeutic implications. Pediatr Clin North Am 2006: 53: 929-959.
7. MICHAUD CM, MURRAY CJ, BLOOM BR. Burden of disease - implications for future research. JAMA 2001: 285: 535-539.
8. MOSCONA A. Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J Clin Invest 2005: 115: 1688-1698.
9. MOSCONA A, PELUSO RW, Relative affinity of the human parainfluenza virus 3 hemagglutinin-neuraminidase for sialic acid correlates with virus-induced fusion activity. J Virol 1993a: 67: 6463-6468.
10. MURRELL M, POROTTO M, WEBER T, GREENGARD O, MOSCONA A. Mutations in human parainfluenza virus type 3 HN causing increased receptor binding activity and resistance to the transition state sialic acid analog 4-GU-DANA (zanamivir). J Virol 2003: 77: 309-317.
11. NICHOLS WG, COREY L, GOOLEY T, DAVIS C, BOECKH M. Parainfluenza virus infections after hematopoietic stem cell transplantation: Risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001: 98: 573-578.
12. POROTTO M, MURRELL M, GREENGARD O, DOCTOR L, MOSCONA A. Influence of the human parainfluenza virus 3 attachment protein's neuraminidase activity on its capacity to activate the fusion protein. J Virol 2005: 79: 2383-2392.
13. POROTTO M, DOCTOR L, CARTA P, et al. Inhibition of Hendra virus membrane fusion. J Virol 2006: 80: 9837-9849.
14. POROTTO M, MURRELL M, GREENGARD O, LAWRENCE M, MCKIMM-BRESCHKIN J, MOSCONA A. Inhibition of parainfluenza type 3 and Newcastle disease virus hemagglutinin-neuraminidase receptor binding: Effect of receptor avidity and steric hindrance at the inhibitor binding sites. J Virol 2004: 78: 13911-13919.
15. POROTTO M, FORNABAIO M, GREENGARD O, MURRELL MT, KELLOGG GE, MOSCONA A. Paramyxovirus receptor-binding molecules: Engagement of one site on the hemagglutinin- neuraminidase protein modulates activity at the second site. J Virol 2006: 80: 1204-1213.
16. POROTTO M, MURRELL M, GREENGARD O, MOSCONA A. Triggering of human parainfluenza virus 3 fusion protein(F) by the hemagglutinin-neuraminidase (HN): An HN mutation diminishing the rate of F activation and fusion. J Virol 2003: 77: 3647-3654.
17. SPARRELID E, LJUNGMAN P, EKELOF-ANDSTROM E, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant 1997: 19: 905-908.
18. WENDT C, WEISDORF D, JORDAN M, BALFOUR H, HERTZ M. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med 1992: 326: 921-926.